Alan Tan (@alantanmd) header
Alan Tan (@alantanmd) profile picture

Genitourinary Oncology, Associate Professor, Vanderbilt University Vice President, MRD Research and Clinical Strategy, Tempus AI

Nashville, TN
Joined June 2009
Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)Photo by Alan Tan (@alantanmd)
Thanks @CureMelanoma for the opportunity to discuss ctDNA in #melanoma, also thanks to my son Auguste for the #cameo appearance! – at Chicago, IL
5
3
55
6,439
Explaining MRD and ctDNA to patients is hard, so we built MRD Watch: free, neutral MRD/ctDNA education. ▪️ Animated explainers ▪️ Curated expert talks ▪️ Active ctDNA trials across all cancers Free weekly updates: mrdwatch.com/subscribe Follow @MRDWatchNews mrdwatch.com
2
4
163
ctDNA-guided adjuvant pembro for MRD+ dMMR tumors, any site (@MSKCancerCenter, @Annals_Oncology) 🧬 ▪️ 184 screened, 12.5% MRD+ ▪️ ctDNA cleared in 11/13 treated ▪️ 5/13 still recurred ▪️ MRD-neg: 2-yr RFS 92% 6 recurred before pembro started. Timing matters. #MRD #ctDNA
5
10
768
FDA granted accelerated approval today to neladalkib (Nelkarmi) for previously treated ALK+ NSCLC. ALKOVE-1 (FDA label): ORR 49% after alectinib, 32% after 2+ ALK TKIs and chemo, and about half of responders still responding at 12 months. Another option after ALK TKI resistance. Data presented by @JessicaJLinMD at #ASCO26 #lcsm
2
2
355
Alan Tan retweeted
Sometimes it's difficult to explain to patients what MRD and ctDNA mean for their cancer. Send them to the new For Patients & Family section on MRD Watch. It has plain-language explainers and a short video on what a ctDNA result actually means. 👉 mrdwatch.com/patients For clinicians, there are accruing ctDNA trials, assay comparisons and the key evidence for every cancer type. Follow @MRDWatchNews for weekly updates and get the free Friday newsletter at mrdwatch.com @MattGalsky @DrRosenbergMSK @LDyrskjot @LauraBukavinaMD @pashtoonkasi @tompowles1 @JeanneTie @skopetz
2
3
5,796
Sometimes it's difficult to explain to patients what MRD and ctDNA mean for their cancer. Send them to the new For Patients & Family section on MRD Watch. It has plain-language explainers and a short video on what a ctDNA result actually means. 👉 mrdwatch.com/patients For clinicians, there are accruing ctDNA trials, assay comparisons and the key evidence for every cancer type. Follow @MRDWatchNews for weekly updates and get the free Friday newsletter at mrdwatch.com @MattGalsky @DrRosenbergMSK @LDyrskjot @LauraBukavinaMD @pashtoonkasi @tompowles1 @JeanneTie @skopetz
2
3
5,796
Honoured and proud to present the results of INTerpath-001 at ESMO: a randomised controlled phase 3 trial of a #personalised therapeutic cancer vaccine. Individualised neoantigen therapy (intismeran) plus pembrolizumab versus pembrolizumab alone, the current standard of care across the world, in high-risk, early-stage melanoma completely removed by surgery (stage IIB to IIID, and some resected stage IV with no evidence of disease). This is cutting-edge science, and it needs to be understood properly. No hype, no noise.  The real data and what they mean for patients. Watch the presentation: melanoma.org.au/news/interpa… At @MelanomaAus our focus is our patients, and curing those we have not yet cured. The therapies my team and I have developed over the last 15 years cure about half of people with stage IV melanoma and prevent stage IV in many with stage II and III. Not everybody, yet. Our multidisciplinary team meeting is world renowned, with leading clinicians with expertise in melanoma and complex skin cancer from diagnosis, management, drug therapies and clinical trials. We discuss the hardest cases, and the evidence we generate shapes clinical practice guidelines around the world. What happens in melanoma impacts other cancers, and we learn from other cancers. Melanoma IS the immunotherapy cancer. #Melanoma #Immunotherapy #INTerpath001 #ESMO26 @myESMO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear
14
72
2,358
🚨 Transformative moment in precision oncology! Targeting the once “undruggable” RAS is becoming clinical reality. 🇪🇺 Daraxonrasib just received EU approval for previously treated metastatic pancreatic cancer! Phase III RASolute 302: median OS 13.2 vs 6.7 months (HR 0.40). Could this be the EV+pembro moment for PDAC? 🔥 Different disease, different mechanism—but a similarly profound shift in treatment. Super exciting times in precision oncology! globenewswire.com/news-relea… @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
10
18
1,148
The PIVOT-006 trial has met its primary end point, demonstrating that adjuvant cretostimogene significantly improved recurrence-free survival vs surveillance following tumor resection in patients with intermediate-risk and high-grade Ta NMIBC. #blcsm urologytimes.com/view/cretos…
2
3
844
“I love the smiles, the dives, the slides and the cellies that conjure visions of that curly-haired dynamo, my kid.” @Cubs CF Pete Crow-Armstrong’s parents leave their son voicemails celebrating his MVP award. 🥲💙
22
523
107
3,316
338,459
Excited to launch mrdwatch.com 🧬 A free, neutral hub for MRD/ctDNA across cancers: the latest data, must-know evidence, MRD-guided trials (incl. accruing), meeting abstracts & videos. For clinicians, patients and advocates. Tell me what to add! #MRD #ctDNA
6
4
1
21
2,142
Grateful for thoughts from more colleagues across the MRD world. @bdermanmd @myelomaMD @DrOlaLandgren @TomMartinMD @CharuAggarwalMD @CharlesSwanton @landau_lab
1
2
157
Alan Tan retweeted
Today the American Cancer Society made important changes to their prostate cancer screening guidelines: Men 50 to 69 should get a PSA test every two years; Black men and men with a family history of prostate cancer should get one every year starting at 45; and starting at age 70, men should talk to their doctors about what's right to them. I know firsthand the toll of this disease, and I know that catching it early saves lives. So talk to your doctor, get screened, and let’s keep working to end cancer as we know it.
486
3,467
129
18,457
1,247,607
When to cut when not to cut 🗡️ can some bladders be saved and answer is yes with right biomarkers combining utDNA and ctDNA to risk stratify to surveillance surgery vs more systemic therapy nicely summarized by @BenjaminPradere #SMU26 read @EUplatinum editorial supporting this as well sciencedirect.com/science/ar…
4
15
1,728
Really excited for this adding @Movember this is a step forward for continued screening and during men’s health awareness month!! @DanaFarber_GU
1
4
131
FDA just approved perioperative EV + durvalumab for cisplatin-ineligible or -refusing MIBC (VOLGA). Just 3 cycles of EV, no adjuvant EV, and 24-mo EFS 63.5% vs 45.1% with cystectomy alone. Do our patients really need 9 cycles of EV? What are you using Monday? 🤔
50%EVP x9 cycles (B15)
12%EV-Durva (VOLGA)
38%EVP then pembro, no EV
8 votes • Final results
1
1
1
305